These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 18992247)

  • 1. Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression.
    Ohta M; Seto M; Ijichi H; Miyabayashi K; Kudo Y; Mohri D; Asaoka Y; Tada M; Tanaka Y; Ikenoue T; Kanai F; Kawabe T; Omata M
    Gastroenterology; 2009 Jan; 136(1):206-16. PubMed ID: 18992247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced expression of RAS protein activator like-1 in gastric cancer.
    Seto M; Ohta M; Ikenoue T; Sugimoto T; Asaoka Y; Tada M; Mohri D; Kudo Y; Ijichi H; Tateishi K; Otsuka M; Hirata Y; Maeda S; Koike K; Omata M
    Int J Cancer; 2011 Mar; 128(6):1293-302. PubMed ID: 20473946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of the Ras regulator RASAL1: another route to Ras activation in colorectal cancer.
    Bernards A; Settleman J
    Gastroenterology; 2009 Jan; 136(1):46-8. PubMed ID: 19041648
    [No Abstract]   [Full Text] [Related]  

  • 4. Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas.
    Fujita M; Fukui H; Kusaka T; Morita K; Fujii S; Ueda Y; Chiba T; Sakamoto C; Kawamata H; Fujimori T
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1277-81. PubMed ID: 11129221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
    Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
    J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations.
    Mahdavinia M; Bishehsari F; Verginelli F; Cumashi A; Lattanzio R; Sotoudeh M; Ansari R; Semeraro D; Hormazdi M; Fakheri H; Rakhshani N; De Lellis L; Curia MC; Cama A; Piantelli M; Malekzadeh R; Iacobelli S; Mariani-Costantini R
    J Cell Physiol; 2008 Aug; 216(2):543-50. PubMed ID: 18330889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues.
    Kim BN; Yamamoto H; Ikeda K; Damdinsuren B; Sugita Y; Ngan CY; Fujie Y; Ogawa M; Hata T; Ikeda M; Ohue M; Sekimoto M; Monden T; Matsuura N; Monden M
    Int J Oncol; 2005 May; 26(5):1217-26. PubMed ID: 15809712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis.
    Ward RL; Todd AV; Santiago F; O'Connor T; Hawkins NJ
    Cancer; 1997 Mar; 79(6):1106-13. PubMed ID: 9070487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene.
    Wang JY; Wang YH; Jao SW; Lu CY; Kuo CH; Hu HM; Hsieh JS; Chong IW; Cheng TL; Lin SR
    Oncol Rep; 2006 Dec; 16(6):1245-52. PubMed ID: 17089045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of FHIT inhibits apoptosis of colorectal cancer: mechanism and clinical implication.
    Cao J; Li W; Xie J; Du H; Tang W; Wang H; Chen X; Xiao W; Li Y
    Surg Oncol; 2006 Dec; 15(4):223-33. PubMed ID: 17382535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative detection of mutant alleles of the K-ras gene with minor groove binder-conjugated fluorogenic DNA probes.
    Itabashi T; Maesawa C; Uchiyama M; Higuchi T; Masuda T
    Int J Oncol; 2004 Mar; 24(3):687-96. PubMed ID: 14767554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases.
    Smakman N; Kranenburg O; Vogten JM; Bloemendaal AL; van Diest P; Borel Rinkes IH
    Clin Cancer Res; 2005 Jan; 11(1):41-8. PubMed ID: 15671526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer.
    Kodach LL; Bleuming SA; Musler AR; Peppelenbosch MP; Hommes DW; van den Brink GR; van Noesel CJ; Offerhaus GJ; Hardwick JC
    Cancer; 2008 Jan; 112(2):300-6. PubMed ID: 18008360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers.
    Endo Y; Marusawa H; Kou T; Nakase H; Fujii S; Fujimori T; Kinoshita K; Honjo T; Chiba T
    Gastroenterology; 2008 Sep; 135(3):889-98, 898.e1-3. PubMed ID: 18691581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enforced expression of RASAL1 suppresses cell proliferation and the transformation ability of gastric cancer cells.
    Qiao F; Su X; Qiu X; Qian D; Peng X; Chen H; Zhao Z; Fan H
    Oncol Rep; 2012 Oct; 28(4):1475-81. PubMed ID: 22825043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EXTL3 promoter methylation down-regulates EXTL3 and heparan sulphate expression in mucinous colorectal cancers.
    Karibe T; Fukui H; Sekikawa A; Shiratori K; Fujimori T
    J Pathol; 2008 Sep; 216(1):32-42. PubMed ID: 18543267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
    Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
    Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR signaling pathway is a target for the treatment of colorectal cancer.
    Zhang YJ; Dai Q; Sun DF; Xiong H; Tian XQ; Gao FH; Xu MH; Chen GQ; Han ZG; Fang JY
    Ann Surg Oncol; 2009 Sep; 16(9):2617-28. PubMed ID: 19517193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of K-ras codon 12 mutations in human feces and ages of patients with colorectal cancer (CRC).
    Chien CC; Chen SH; Liu CC; Lee CL; Yang RN; Yang SH; Huang CJ
    Transl Res; 2007 Feb; 149(2):96-102. PubMed ID: 17240321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers.
    Kodach LL; Wiercinska E; de Miranda NF; Bleuming SA; Musler AR; Peppelenbosch MP; Dekker E; van den Brink GR; van Noesel CJ; Morreau H; Hommes DW; Ten Dijke P; Offerhaus GJ; Hardwick JC
    Gastroenterology; 2008 May; 134(5):1332-41. PubMed ID: 18471510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.